Fig. 1 · Structure

Documents & Downloads

Sotrastaurin (AEB071)

Cat. No. A11554 CAS 425637-18-9

PKC inhibitor

Sotrastaurin is a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PKCθ ki 0.22nM
PKCβ1 ki 0.64nM
PKCα ki 0.95nM
PKCη ki 1.8nM
PKCδ ki 2.1nM
PKCε ki 3.2nM

6 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 3.2 μM Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay [PMID: 33100009]
ASPC1 IC50 > 3.2 μM Cytotoxicity in human ASPC1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay [PMID: 33100009]
Bone marrow cell IC50 3.7 μM Antiproliferative activity against CBA mouse bone marrow cells assessed as inhibition of [3H]thymidine incorporation after 4 days [PMID: 19827831]
BXPC-3 IC50 > 3.2 μM Cytotoxicity in human BXPC-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay [PMID: 33100009]
Jurkat IC50 54 nM Inhibition of TCR/CD28-mediated human T cell activation in Jurkat cells expressing human IL2 promoter by luciferase reporter gene assay [PMID: 19827831]
Lymphocyte IC50 150 nM Immunosuppressive activity in mouse lymphocytes assessed as alloantigen-induced T cell proliferation by mixed lymphocyte reaction assay [PMID: 21797275]
Lymphocyte IC50 37 nM Immunosuppressive activity in human lymphocytes assessed as alloantigen-induced T cell proliferation by mixed lymphocyte reaction assay [PMID: 21797275]
MGC-803 IC50 > 3.2 μM Cytotoxicity in human MGC-803 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay [PMID: 33100009]
NCI-H1299 IC50 > 3.2 μM Cytotoxicity in human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay [PMID: 33100009]
NCI-H1975 IC50 > 3.2 μM Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay [PMID: 33100009]
PBMC IC50 28 nM Inhibition of human PBMC proliferation assessed as decrease in [3H]-TdR uptake after 6 days by mixed lymphocyte reaction assay [PMID: 28131714]
PC-9 IC50 > 3.2 μM Cytotoxicity in human PC-9 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay [PMID: 33100009]
RKO IC50 > 3.2 μM Cytotoxicity in human RKO cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay [PMID: 33100009]
Splenocyte IC50 128 nM Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of [3H]thymidine incorporation after 4 days by allogenic mixed lymphocyte reaction assay [PMID: 19827831]
Splenocyte IC50 34 nM Immunosuppressive activity in human splenocytes assessed as inhibition of [3H]thymidine incorporation after 4 days by allogenic mixed lymphocyte reaction assay [PMID: 19827831]
Vero CC50 66 μM Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured on day 5 post dose by MTS/PMS based microscopic analysis [PMID: 28689975]

16 records · Scroll to view more

Sotrastaurin (AEB071) Research Summary

This section summarizes 4 in vitro studies of Sotrastaurin (AEB071) from 3 published references. In vitro models include DND-41 parental cells; SPASM PKCα sensors.

Sotrastaurin (AEB071) In Vitro Studies

In DND-41 parental cells treated with Sotrastaurin, PKCδ inhibition alone significantly increased cMyc protein expression compared with DMSO-treated controls. Sotrastaurin substantially inhibited the regulatory–kinase domain interaction in SPASM PKCα sensors, as reported by changes in the FRET ratio. In PHGDH-overexpressing MHCC-97H cells supplemented with or without Sotrastaurin, the compound partially restored mitochondrial membrane potential. Following Sotrastaurin pretreatment and subsequent GSI treatment, continuous PKCδ inhibition completely abolished the rescue of cell growth in the comparison of untreated and Sotrastaurin-treated persister cells. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

cMyc Protein Expression in Parental Cells

Cell-based study · DND-41 parental cells [1]

DND-41 parental cells were treated with Sotrastaurin and compared with DMSO-treated controls. PKCδ inhibition alone resulted in a significant increase in cMyc protein expression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cMyc protein expressionReported result PKCδ inhibition alone resulted in a significant increase in cMyc protein expression in parental cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
for 5 days
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Sotrastaurin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Notch and PKC inhibition synergistically affects resistant T-ALL cells’ survival (S215, S220, S235, S237); Results > PKCδ is indispensable for the development of adaptive GSI resistance (S272)

cMyc protein expression: cMyc protein expression; comparator: Ctrl DMSO-treated cells — Results > Notch and PKC inhibition synergistically affects resistant T-ALL cells’ survival (S237)

Regulatory–Kinase Domain Interaction in PKCα Sensors

Cell-based study · SPASM PKCα sensors [2]

SPASM PKCα sensors were treated with Sotrastaurin and compared with the no-inhibitor condition. Treatment substantially inhibited the regulatory–kinase domain interaction, as reported by changes in the FRET ratio.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
regulatory-kinase domain interaction as reported by changes in the FRET ratioReported result substantially inhibited this interaction[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
incubated at room temperature for 30 min before measurement
Method
Proteins were treated with inhibitors
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Sotrastaurin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Select ATP-competitive SMKIs displace regulatory-kinase domain interactions (S2, S5, S6); Experimental procedures > Experimental methods > FRET measurements (S99, S102); Figure 1 legend (S231)

regulatory-kinase domain interaction as reported by changes in the FRET ratio: regulatory-kinase domain interaction as reported by changes in the FRET ratio; comparator: no inhibitor condition (apo) — Results > Select ATP-competitive SMKIs displace regulatory-kinase domain interactions (S5, S6)

Mitochondrial Membrane Potential in PHGDH-Overexpressing Cells

Cell-based study · PHGDH-overexpressing MHCC-97H cells [3]

PHGDH-overexpressing MHCC-97H cells were supplemented with or without Sotrastaurin. Sotrastaurin partially restored mitochondrial membrane potential in this comparison.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mitochondrial membrane potentialReported result partially restored the membrane potential[3]

Literature-Reported Treatment Conditions

Treatment concentration
2 μM
Exposure duration
24 h
Method
supplemented
Co-treatment
Other interventions in this design: PHGDH. Compound effect isolated by the comparison: PHGDH-overexpressing MHCC-97H cells supplemented with or without sotrastaurin.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Sotrastaurin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > PHGDH promotes mitophagy via PRKCD (S68, S69, S75)

mitochondrial membrane potential: mitochondrial membrane potential; comparator: PHGDH-overexpressing MHCC-97H cells supplemented with or without sotrastaurin — Results > PHGDH promotes mitophagy via PRKCD (S69, S75)

Cell Growth Rescue in Drug-Tolerant Persister Cells

Cell-based study · DND-41 parental cells [1]

DND-41 parental cells were pretreated with Sotrastaurin before GSI treatment. In the comparison of untreated and Sotrastaurin-treated persister cells under GSI treatment, continuous PKCδ inhibition completely abolished the rescue of cell growth.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Live cell count was performed by trypan blue exclusionReported result continuous PKCδ inhibition completely abolished the rescue of cell growth of drug-tolerant persister cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
pretreated with sotrastaurin (5 μM) for 3 days. Next, GSI treatment (0.5 μM) was performed up to 5 weeks
Vehicle
DMSO
Co-treatment
Other interventions in this design: GSI 0.5 μM. Compound effect isolated by the comparison: untreated and sotrastaurin-treated persister cells.
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Sotrastaurin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > PKCδ is indispensable for the development of adaptive GSI resistance (S264, S265, S266, S272, S273, S274); Methods > Drug treatment (S294)

Live cell count was performed by trypan blue exclusion: Live cell count was performed by trypan blue exclusion; comparator: persister cells (DMSO + GSI) — Results > PKCδ is indispensable for the development of adaptive GSI resistance (S266, S274)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 425637-18-9
Applications PKC inhibitor
Formula C25H22N6O2
Molecular Weight 438.5
Synonyms AEB 071
SMILES
CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O)C5=CNC6=CC=CC=C65

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 79 mg/mL (180.17 mM)
Water Insoluble
Ethanol 2 mg/mL (4.56 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+30% PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Sotrastaurin (AEB071) Research References

  1. [1] Franciosa G, Smits JGA, Minuzzo S, et al. Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures. Nat Commun (2021). PMID: 33947863 DOI: 10.1038/s41467-021-22787-9 Source material
  2. [2] Lippert LG, Ma N, Ritt M, et al. Kinase inhibitors allosterically disrupt a regulatory interaction to enhance PKCα membrane translocation. J Biol Chem (2021). PMID: 33508318 DOI: 10.1016/j.jbc.2021.100339 Source material
  3. [3] Cheng B, Peng P, Chen S, et al. Phosphoglycerate dehydrogenase stabilizes protein kinase C delta type mRNA to promote hepatocellular carcinoma progression. Signal Transduct Target Ther (2025). PMID: 40681503 DOI: 10.1038/s41392-025-02304-w Source material

Added to your cart

View Cart Checkout
Loading...